{"disease":{"id":"non-gcb-abc-diffuse-large-b-cell-lymphoma","name":"non gcb abc diffuse large b cell lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04835870","title":"Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04796857","title":"Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT05319028","title":"Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}